1 |
NCT00435214 |
Recruiting |
Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer |
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Other
|
- CIN2+/CIN3+/Cancer
- HPV Clearance
|
135600 |
Female |
21 Years to 100 Years (Adult, Senior) |
NCT00435214 |
999907079 07-C-N079 |
|
January 29, 2007 |
|
|
February 14, 2007 |
April 4, 2018 |
|
- Kaiser Permanente Northern California
Oakland, California, United States
|
2 |
NCT03426878 |
Not yet recruiting |
Cancer Health Assessments Reaching Many |
- Hereditary Cancer Syndrome
|
- Other: Modified genetic counseling
- Other: Traditional genetic counseling
|
Interventional |
Not Applicable |
- Kaiser Permanente
- National Human Genome Research Institute (NHGRI)
- University of Washington
- (and 7 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Screening
|
- Positive findings for hereditary cancer syndromes
- Positive findings for other medically actionable genetic conditions
- Positive findings for a selected list of carrier conditions
- (and 6 more...)
|
880 |
All |
18 Years to 50 Years (Adult) |
NCT03426878 |
2U01HG007292-05 |
CHARM |
May 1, 2018 |
May 31, 2020 |
May 31, 2021 |
February 8, 2018 |
February 8, 2018 |
|
|
3 |
NCT03167125 |
Recruiting |
Participatory Research to Advance Colon Cancer Prevention |
|
- Other: Automated Prompts
- Other: Automated Plus Live Prompts
|
Interventional |
Not Applicable |
- Kaiser Permanente
- Oregon Health and Science University
- AltaMed Health Services
- Kaiser Permanente
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Increased colorectal cancer screening rates
|
15000 |
All |
50 Years to 75 Years (Adult, Senior) |
NCT03167125 |
1U01MD010665-01 |
PROMPT |
September 5, 2017 |
July 31, 2020 |
July 31, 2020 |
May 25, 2017 |
October 5, 2017 |
|
- AltaMed Garden Grove
Garden Grove, California, United States - AltaMed Pico
Pico Rivera, California, United States
|
4 |
NCT02941614 |
Recruiting |
Implementing Systematic Distress Screening in Breast Cancer |
|
- Behavioral: Distress screening
|
Observational |
|
- Kaiser Permanente
- California Breast Cancer Research Program
- Kaiser Permanente
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Proportion screened for distress
- Functional Assessment of Cancer Therapy, Breast Cancer (FACT-B)
- Breast Cancer Prevention Trial (BCPT) Symptom Checklist
|
1200 |
Female |
18 Years and older (Adult, Senior) |
NCT02941614 |
KPSC IRB 11103 |
|
October 2, 2017 |
September 2019 |
September 2019 |
October 21, 2016 |
October 11, 2017 |
|
- Anaheim Medical Center
Anaheim, California, United States - South Bay - Harbor City Medical Center
Harbor City, California, United States - Los Angeles Medical Center
Los Angeles, California, United States
|
5 |
NCT03029286 |
Recruiting |
ENGAGED 2 Study: Experiences With Mammography Screening and Breast Density 2 |
- Breast Density
- Breast Cancer Female
|
- Behavioral: Usual Care Arm
- Behavioral: Personalized Web Intervention Arm
|
Interventional |
Not Applicable |
- Georgetown University
- Kaiser Permanente
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
- Uptake of chemoprevention gathered via health plan pharmacy records at 12 months
- Distress gathered via self-report distress thermometer at 6-weeks and 12 months after recruitment
- Breast MRI gathered via health plan records at 12 months
|
1250 |
Female |
40 Years to 69 Years (Adult, Senior) |
NCT03029286 |
2015-0687 |
|
February 15, 2017 |
August 2018 |
August 2019 |
January 24, 2017 |
September 1, 2017 |
|
- Kaiser Permanente Washington Health Research Institute
Seattle, Washington, United States
|
6 |
NCT03078608 |
Recruiting |
POEM (Practice Of Embracing Each Moment) STUDY |
- Distress
- Cancer
- Chemotherapy Effect
|
- Behavioral: Mindfulness meditation program (administered via mobile app)
- Behavioral: Progressive muscle relaxation (via mobile app)
|
Interventional |
Not Applicable |
- Kaiser Permanente
- American Cancer Society, Inc.
- Kaiser Permanente
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Change in anxiety and depression
- Change in distress
- Change in fatigue
- (and 4 more...)
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT03078608 |
CN-17-2851 |
POEM |
October 24, 2017 |
April 2018 |
October 2019 |
March 13, 2017 |
October 25, 2017 |
|
- Kaiser Permanente Northern California
Oakland, California, United States
|
7 |
NCT03471221 |
Recruiting |
Helping Improve Pediatric Patient Outcomes |
- Pediatric Cancer, Animal-Assisted Activities
|
- Behavioral: Therapy Dog Visit
|
Interventional |
Not Applicable |
- Kaiser Permanente
- Seattle Children's Hospital
- Kaiser Permanente
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Pediatric Quality of Life Inventory Present Functioning Visual Analogue Scales (PedsQL VAS) total distress score
- Microbial load (colony forming units; cfu) on child hands
- Pediatric Quality of Life Inventory Present Functioning Visual Analogue Scales (PedsQL VAS) individual scales (afraid/scared, sad/blue, angry, worry, tired, pain/hurt)
- (and 9 more...)
|
50 |
All |
6 Years to 17 Years (Child) |
NCT03471221 |
1R21HD091877 |
HIPPO |
March 19, 2018 |
March 2019 |
April 2019 |
March 20, 2018 |
March 27, 2018 |
|
- Kaiser Permanente Washington Health Research Institute
Seattle, Washington, United States - Kaiser Permanente Washington Health Research Institute
Seattle, Washington, United States
|
8 |
NCT02302196 |
Recruiting |
Autologous Fat Grafting of the Breast in Women With Post Lumpectomy Contour Defects |
- Cancer of the Breast
- Anomaly of Breast
|
- Procedure: Autologous Fat Grafting of the Breast
- Other: Control Arm
|
Observational |
|
- Kaiser Permanente
- Kaiser Permanente
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Safety of Autologous Fat Grafting (AFG) compared to standard breast reconstruction for lumpectomy, as measured by the BIRADS scores
- Women undergoing Autologous Fat (AFG) Grafting of the breast
|
100 |
Female |
18 Years and older (Adult, Senior) |
NCT02302196 |
KPNW Fat Grafting 001 |
|
September 2015 |
January 2022 |
January 2022 |
November 26, 2014 |
March 13, 2017 |
|
- Kaiser Permanente NW Region, Sunnybrook Medical Office Building
Clackamas, Oregon, United States
|
9 |
NCT02243748 |
Recruiting |
Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non-small Cell Lung Cancer and Their Family Caregivers |
- Caregiver
- Psychological Impact of Cancer and Its Treatment
- Recurrent Non-small Cell Lung Cancer
- (and 5 more...)
|
- Other: Palliative Therapy
- Other: quality-of-life assessment
- Other: questionnaire administration
|
Interventional |
Not Applicable |
- City of Hope Medical Center
- National Cancer Institute (NCI)
- National Institute of Nursing Research (NINR)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Impact of the PCI on symptom control as compared to the usual care group
- Impact of the PCI on patient QOL as compared to the usual care group
- Impact of the PCI on psychological distress as compared to the usual care group
- (and 5 more...)
|
385 |
All |
18 Years and older (Adult, Senior) |
NCT02243748 |
14206 NCI-2014-01926 1R01NR015341-01 |
|
February 2015 |
February 2019 |
February 2019 |
September 18, 2014 |
October 18, 2017 |
|
- City of Hope Medical Center
Duarte, California, United States - Southern California Permanente Medical Group
Irvine, California, United States - Kaiser Permanente-Ontario Vineyard Medical Offices and Ambulatory SurgiCenter
Ontario, California, United States - (and 2 more...)
|
10 |
NCT02355262 |
Recruiting |
CATCH-UP Intervention in Increasing Cancer Screening and Prevention Care in Uninsured Patients at Community Health Centers |
- Breast Carcinoma
- Cervical Carcinoma
- Colorectal Carcinoma
- (and 3 more...)
|
- Other: Informational Intervention
|
Observational |
|
- OHSU Knight Cancer Institute
- Kaiser Permanente Northwest Center for Health Research
- National Cancer Institute (NCI)
- (and 2 more...)
|
Other / NIH |
- Observational Model: Ecologic or Community
- Time Perspective: Prospective
|
- Changes in the proportion of clinic patients who receive age- and gender-appropriate recommended cancer screening and preventive care (clinic-level)
- Changes in the proportion of clinic patients with insurance continuity
- Total number of months uninsured (total gap months)
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT02355262 |
IRB00009862 NCI-2014-02326 CR00024554 5219 MR00042926 MR00044877 P30CA069533 R01CA181452 |
|
July 1, 2014 |
June 30, 2019 |
June 30, 2019 |
February 4, 2015 |
December 27, 2017 |
|
- OHSU Knight Cancer Institute
Portland, Oregon, United States
|
11 |
NCT03394885 |
Not yet recruiting |
Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer |
- Ovarian Cancer
- Ovarian Neoplasms
|
- Drug: Atezolizumab
- Drug: Carboplatin
- Drug: Paclitaxel
|
Interventional |
Phase 1 Phase 2 |
- Duke University
- Johns Hopkins University
- Genentech, Inc.
- Kaiser Permanente
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety: Incidence of post chemotherapy surgical debulking
- Safety: Incidence of treatment emergent adverse events
- Safety: Dose intensity
- (and 5 more...)
|
40 |
Female |
18 Years and older (Adult, Senior) |
NCT03394885 |
Pro00079313 |
AdORN |
May 2018 |
January 2021 |
June 2022 |
January 9, 2018 |
April 10, 2018 |
|
- Duke Cancer Institute
Durham, North Carolina, United States
|
12 |
NCT01813877 |
Recruiting |
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma |
|
|
Interventional |
Not Applicable |
- Jonsson Comprehensive Cancer Center
- Kaiser Permanente
- The Methodist Hospital System
- Jonsson Comprehensive Cancer Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Diagnostic accuracy compared to standard diagnostics without PET
- Impact of FDOPA PET on patient management
|
360 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT01813877 |
FDOPA12-000939 |
|
September 22, 2012 |
September 22, 2018 |
September 22, 2020 |
March 19, 2013 |
November 30, 2017 |
|
- UCLA
Los Angeles, California, United States
|
13 |
NCT01901094 |
Recruiting |
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy |
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
|
- Procedure: Axillary Lymph Node Dissection (ALND)
- Radiation: Nodal Radiation Therapy
- Radiation: Axillary Radiation Therapy
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Invasive breast cancer recurrence-free interval (IBC-RFI)
- Overall survival
- Ipsilateral/local/regional invasive breast cancer recurrence (ILR-REC)
|
2918 |
All |
18 Years and older (Adult, Senior) |
NCT01901094 |
A011202 U10CA031946 NCI-2013-00875 |
|
February 2014 |
January 2024 |
|
July 17, 2013 |
April 9, 2018 |
|
- Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - Southern Cancer Center PC-Providence
Mobile, Alabama, United States - (and 1091 more...)
|
14 |
NCT01515787 |
Recruiting |
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery |
|
- Drug: FOLFOX (chemotherapy)
- Other: 5 FUCMT (chemoradiation)
- Procedure: surgery
- Procedure: magnetic resonance imaging or endorectal ultrasound
|
Interventional |
Phase 2 Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pelvic R0 resection rate (Phase II)
- DFS (Phase III)
- Time to local recurrence (TLR)
- (and 4 more...)
|
1120 |
All |
18 Years and older (Adult, Senior) |
NCT01515787 |
N1048 CDR0000715321 NCI-2012-00234 U10CA031946 |
|
January 2012 |
January 2021 |
|
January 24, 2012 |
April 9, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1030 more...)
|
15 |
NCT02445391 |
Recruiting |
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy |
- Estrogen Receptor Negative
- HER2/Neu Negative
- Invasive Breast Carcinoma
- (and 9 more...)
|
- Drug: Capecitabine
- Drug: Carboplatin
- Drug: Cisplatin
- (and 3 more...)
|
Interventional |
Phase 3 |
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Invasive disease-free survival (IDFS) of patients with basal-like triple-negative breast cancer (TNBC)
- Incidence of toxicity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Overall survival (OS) of patients with basal-like triple-negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy
- (and 3 more...)
|
562 |
All |
18 Years and older (Adult, Senior) |
NCT02445391 |
EA1131 NCI-2014-01820 U10CA180820 U24CA196172 |
|
April 29, 2015 |
May 31, 2019 |
May 31, 2024 |
May 15, 2015 |
December 8, 2017 |
|
- University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 846 more...)
|
16 |
NCT03278340 |
Not yet recruiting |
Using Technology to Scale-Up an Occupational Sun Protection Policy Program |
|
- Behavioral: Sun Safe Workplaces - Technology
- Behavioral: Sun Safe Workplaces -In Person
|
Interventional |
Not Applicable |
- Klein Buendel, Inc.
- Kaiser Permanente
- University of Colorado, Denver
- National Cancer Institute (NCI)
|
Industry / Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
- Implementation of Occupational Sun Protection Policy
- Implementation of Sun Safety Education
- Economic Evaluation of the SSW-IP and SSW-T Intervention Programs
- (and 3 more...)
|
11394 |
All |
18 Years and older (Adult, Senior) |
NCT03278340 |
R01CA210259 0316 |
SSW-T |
April 15, 2018 |
June 30, 2022 |
July 31, 2022 |
September 11, 2017 |
March 9, 2018 |
|
- Kaiser Foundation Research Institute
Oakland, California, United States - University of Colorado Denver
Aurora, Colorado, United States - Klein Buendel, Inc.
Golden, Colorado, United States
|
17 |
NCT01674140 |
Recruiting |
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer |
|
- Drug: anastrozole
- Drug: everolimus
- Drug: exemestane
- (and 5 more...)
|
Interventional |
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- IDFS using a stratified log-rank test, assessed up to 10 years
- OS estimates will be based on Kaplan-Meier procedures, assessed up to 10 years
- DRFS, assessed up to 10 years
- Toxicity based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, assessed up to 10 years
|
1900 |
All |
18 Years and older (Adult, Senior) |
NCT01674140 |
S1207 U10CA032102 NCI-2012-01995 |
e3 |
April 2013 |
December 2022 |
January 2030 |
August 28, 2012 |
March 21, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1432 more...)
|
18 |
NCT03377556 |
Recruiting |
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer |
- ATM Gene Mutation
- ATR Gene Mutation
- BARD1 Gene Mutation
- (and 18 more...)
|
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Drug: Talazoparib
|
Interventional |
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate assessed by Response Evaluation Criteria in Solid Tumors 1.1 (Design #2)
- Duration of response (Design #2)
- Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Design #2)
- (and 2 more...)
|
64 |
All |
Child, Adult, Senior |
NCT03377556 |
S1400G NCI-2017-00135 U10CA180888 |
|
February 7, 2017 |
May 1, 2022 |
December 2024 |
December 19, 2017 |
April 20, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1113 more...)
|
19 |
NCT03373760 |
Recruiting |
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer |
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
|
- Biological: Durvalumab
- Other: Laboratory Biomarker Analysis
- Biological: Tremelimumab
|
Interventional |
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Duration of response (DOR)
- Immune-Related Response Criteria investigator-assessed progression-free survival (irRC-IA-PFS) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- (and 3 more...)
|
132 |
All |
Child, Adult, Senior |
NCT03373760 |
S1400F NCI-2016-01597 U10CA180888 |
|
October 2, 2017 |
April 1, 2022 |
April 1, 2022 |
December 14, 2017 |
December 14, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 1018 more...)
|
20 |
NCT02927249 |
Recruiting |
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy |
- Node Positive HER2 Negative Breast Cancer
|
- Other: Placebo
- Drug: Aspirin
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- United States Department of Defense
- (and 2 more...)
|
Other / NIH / U.S. Fed / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Invasive disease-free survival (iDFS)
- Overall survival (OS)
- Distant disease free survival (DDFS)
- (and 2 more...)
|
2936 |
All |
18 Years to 69 Years (Adult, Senior) |
NCT02927249 |
A011502 NCI-2016-00233 U10CA180821-01 |
|
December 2016 |
April 2021 |
|
October 7, 2016 |
April 9, 2018 |
|
- Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - Southern Cancer Center PC-Providence
Mobile, Alabama, United States - (and 1176 more...)
|
21 |
NCT00632853 |
Recruiting |
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide |
|
- Radiation: Standard Radiation Dose Therapy
- Drug: cisplatin
- Drug: etoposide
- (and 2 more...)
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival time between 3 treatment arms
- Complete and partial response rates
- Failure-free survival
|
729 |
All |
18 Years and older (Adult, Senior) |
NCT00632853 |
CALGB-30610 RTOG 0538 U10CA031946 CDR0000588879 NCI-2009-00470 |
|
March 2008 |
June 2023 |
|
March 11, 2008 |
April 9, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - The Kirklin Clinic at Acton Road
Birmingham, Alabama, United States - Providence Hospital
Mobile, Alabama, United States - (and 897 more...)
|
22 |
NCT02194738 |
Recruiting |
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) |
- Large Cell Lung Carcinoma
- Lung Adenocarcinoma
- Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- (and 9 more...)
|
- Other: Cytology Specimen Collection Procedure
- Other: Laboratory Biomarker Analysis
|
Observational |
|
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
|
- Central clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105, as measured by rate of accrual
- Feasibility of research grade formalin-fixed, paraffin-embedded tissue collection for Center for Cancer Genomics (CCG) analysis, as measured by adequate specimens collected per month
- Disease free survival (DFS) rate for lung cancers which are wild-type for EGFR and ALK
- Agreement of local genotyping methods (direct sequencing of EGFR, ALK fluorescence in situ hybridization [FISH]) with central Clinical Laboratory Improvement Amendments genotyping
|
8300 |
All |
18 Years and older (Adult, Senior) |
NCT02194738 |
NCI-2014-01509 A151216 U10CA180821 U10CA180830 U10CA031946 |
|
August 18, 2014 |
September 28, 2021 |
September 28, 2021 |
July 18, 2014 |
April 20, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1330 more...)
|
23 |
NCT02785952 |
Recruiting |
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers |
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
|
- Biological: Ipilimumab
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
- (and 2 more...)
|
Interventional |
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Investigator-assessed progression-free survival as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (Design #1, Phase II)
- Less than 33% improvement in median investigator-assessed progression-free survival as defined as Response Evaluation Criteria in Solid Tumors version 1.1 (Design #1, Phase III)
- Overall survival
- (and 4 more...)
|
350 |
All |
18 Years and older (Adult, Senior) |
NCT02785952 |
S1400I NCI-2016-00050 U10CA180888 |
|
December 18, 2015 |
April 1, 2022 |
April 1, 2022 |
May 30, 2016 |
April 10, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1177 more...)
|
24 |
NCT02728804 |
Recruiting |
S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer |
- Stage IVA Colon Cancer
- Stage IVA Rectal Cancer
- Stage IVB Colon Cancer
- Stage IVB Rectal Cancer
|
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
|
Observational |
|
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of treatment-related major financial hardship, defined as one or more of the following: debt accumulation of any amount, selling or refinancing home, >= 20% income decline, borrowing money of any amount from family/friends
- Accrual to a prospective-multi-site longitudinal cohort study
- Caregiver participation
- (and 8 more...)
|
374 |
All |
18 Years and older (Adult, Senior) |
NCT02728804 |
S1417CD NCI-2015-01885 S1417 SWOG-S1417CD UG1CA189974 |
|
April 2016 |
June 2020 |
June 2020 |
April 5, 2016 |
February 2, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 509 more...)
|
25 |
NCT02954874 |
Recruiting |
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer |
- Estrogen Receptor Negative
- HER2/Neu Negative
- Invasive Breast Carcinoma
- (and 13 more...)
|
- Other: Laboratory Biomarker Analysis
- Other: Patient Observation
- Biological: Pembrolizumab
- (and 3 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Invasive disease-free survival (IDFS)
- Severity of fatigue measured by Patient Reported Outcomes Measurement Information System (PROMIS) fatigue scale
- Physical function reported by patients measured by Patient Reported Outcomes Measurement Information System (PROMIS) Global physical health scale
- (and 11 more...)
|
1000 |
All |
18 Years and older (Adult, Senior) |
NCT02954874 |
NCI-2016-01595 S1418/BR006 s16-02231 S1418 U10CA180888 |
|
November 15, 2016 |
May 31, 2026 |
|
November 4, 2016 |
April 24, 2018 |
|
- Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - Southern Cancer Center PC-Providence
Mobile, Alabama, United States - (and 557 more...)
|
26 |
NCT02438722 |
Recruiting |
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer |
- Recurrent Non-Small Cell Lung Carcinoma
- Stage IV Non-Small Cell Lung Cancer
|
- Drug: Afatinib Dimaleate
- Biological: Cetuximab
- Other: Laboratory Biomarker Analysis
|
Interventional |
Phase 2 Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- OS (phase III)
- PFS (phase II)
- PFS
- (and 4 more...)
|
605 |
All |
Child, Adult, Senior |
NCT02438722 |
S1403 NCI-2014-02405 BI 1200.124 U10CA180888 |
|
March 2015 |
February 2020 |
February 2022 |
May 8, 2015 |
April 10, 2018 |
|
- Mercy Hospital Fort Smith
Fort Smith, Arkansas, United States - CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas, United States - Fowler Family Center for Cancer Care
Jonesboro, Arkansas, United States - (and 635 more...)
|
27 |
NCT02446600 |
Recruiting |
Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- BRCA Rearrangement
- Deleterious BRCA1 Gene Mutation
- Deleterious BRCA2 Gene Mutation
- (and 12 more...)
|
- Drug: Carboplatin
- Drug: Cediranib Maleate
- Drug: Gemcitabine Hydrochloride
- (and 6 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- AstraZeneca
- National Cancer Institute (NCI)
|
NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival determined using Response Evaluation Criteria in Solid Tumors version 1.1 criteria
- Overall survival
- Frequency and severity of adverse effects
- Patient reported scores of disease-related symptoms as measured by the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 Disease-Related Symptom-Physical
|
549 |
Female |
19 Years and older (Adult, Senior) |
NCT02446600 |
NCI-2015-00606 NRG-GY004 s16-01480 U10CA180868 |
|
February 4, 2016 |
December 31, 2019 |
|
May 18, 2015 |
April 23, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Alaska Women's Cancer Care
Anchorage, Alaska, United States - (and 357 more...)
|
28 |
NCT02750826 |
Recruiting |
Breast Cancer WEight Loss Study (BWEL Study) |
|
- Other: Health Education Program
- Other: Weight Loss Intervention
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Division of Cancer Control
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Invasive disease-free survival
- Overall survival
- Distant disease-free survival
- (and 20 more...)
|
3136 |
Female |
18 Years and older (Adult, Senior) |
NCT02750826 |
A011401 NCI-2015-01918 |
|
August 2016 |
May 2030 |
|
April 26, 2016 |
April 9, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 1259 more...)
|
29 |
NCT03279133 |
Recruiting |
Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients. |
- Hematopoietic Stem Cell Transplantation
|
- Drug: Ledipasvir 90mg/Sofosubvir 400mg
|
Interventional |
Phase 4 |
- Kaiser Permanente
- City of Hope National Medical Center
- Kaiser Permanente
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and Tolerability of LDV/SOF Treatment in Candidates for HCT with hepatitis C infection
- Rate of HCV Relapse Post HCT
- Effect of Virologic Suppression on Post HCT Complications
- (and 3 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT03279133 |
IN-US-337-2116 |
|
September 1, 2017 |
August 2018 |
August 2021 |
September 12, 2017 |
September 18, 2017 |
|
- City of Hope
Duarte, California, United States - Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States
|
30 |
NCT02749903 |
Recruiting |
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers |
|
|
Interventional |
Phase 2 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Astellas Pharma US, Inc.
- Alliance for Clinical Trials in Oncology
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- best overall response rate
- progression-free survival
- adverse events (The maximum grade for each type of adverse event will be summarized using CTCAE version 4.0.)
- adverse events (The frequency and percentage of grade 3+ adverse events will be summarized using CTCAE version 4.0.)
|
45 |
All |
18 Years and older (Adult, Senior) |
NCT02749903 |
A091404 NCI-2015-01706 |
|
June 2016 |
April 2018 |
|
April 25, 2016 |
April 9, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 280 more...)
|
31 |
NCT02488967 |
Recruiting |
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer |
- Breast Adenocarcinoma
- Estrogen Receptor Negative
- HER2/Neu Negative
- (and 7 more...)
|
- Drug: Carboplatin
- Drug: Cyclophosphamide
- Drug: Doxorubicin Hydrochloride
- (and 2 more...)
|
Interventional |
Phase 3 |
- NRG Oncology
- National Cancer Institute (NCI)
- NRG Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- IDFS
- BCFS
- DRFI
- (and 3 more...)
|
990 |
All |
18 Years and older (Adult, Senior) |
NCT02488967 |
NRG-BR003 NCI-2015-00128 NRG-BR1428 U10CA180868 |
|
July 2015 |
April 2021 |
|
July 2, 2015 |
October 5, 2016 |
|
- Southern Cancer Center PC-Providence
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1076 more...)
|
32 |
NCT02867592 |
Recruiting |
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors |
- Adrenal Cortex Carcinoma
- Adult Alveolar Soft Part Sarcoma
- Adult Clear Cell Sarcoma of Soft Parts
- (and 30 more...)
|
- Drug: Cabozantinib S-malate
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response assessed by Response Evaluation Criteria in Solid Tumors version 1.1
- Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Pharmacokinetics (PK) parameters of cabozantinib s-malate
|
146 |
All |
2 Years to 30 Years (Child, Adult) |
NCT02867592 |
NCI-2016-01258 ADVL1622 U10CA180886 |
|
May 8, 2017 |
November 21, 2018 |
November 21, 2018 |
August 16, 2016 |
April 24, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 119 more...)
|
33 |
NCT02513394 |
Recruiting |
PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer |
|
- Drug: Palbociclib
- Drug: Standard Adjuvant Endocrine Therapy
|
Interventional |
Phase 3 |
- Alliance Foundation Trials, LLC.
- Austrian Breast & Colorectal Cancer Study Group
- NSABP Foundation Inc
- (and 3 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Invasive Disease Free Survival (iDFS)
- To compare the safety of 2 years of palbociclib with adjuvant endocrine therapy versus adjuvant endocrine therapy alone. (distant recurrence-free survival (DRFS), locoregional recurrences-free survival (LRRFS), and overall survival (OS)
|
4600 |
All |
18 Years and older (Adult, Senior) |
NCT02513394 |
AFT-05 ABCSG 42 BIG 14-03 2014-005181-30 |
PALLAS |
August 2015 |
September 2020 |
September 2025 |
July 31, 2015 |
April 12, 2018 |
|
- University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Southern Cancer Center
Mobile, Alabama, United States - Katmai Oncology Group
Anchorage, Alaska, United States - (and 233 more...)
|
34 |
NCT02921256 |
Recruiting |
Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer |
- Rectal Adenocarcinoma
- Stage II Rectal Cancer AJCC v7
- Stage III Rectal Cancer AJCC v7
|
- Drug: Capecitabine
- Drug: Fluorouracil
- Radiation: Intensity-Modulated Radiation Therapy
- (and 4 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in NAR score
- OS
- DFS
- (and 11 more...)
|
174 |
All |
18 Years and older (Adult, Senior) |
NCT02921256 |
NCI-2016-00222 NRG-GI002 s17-00197 U10CA180868 |
|
October 12, 2016 |
April 30, 2019 |
|
October 3, 2016 |
April 23, 2018 |
|
- University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - (and 515 more...)
|
35 |
NCT03038100 |
Recruiting |
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Neoplasms
|
- Drug: Paclitaxel
- Drug: Carboplatin
- Drug: Atezolizumab
- (and 2 more...)
|
Interventional |
Phase 3 |
- Hoffmann-La Roche
- GOG Foundation
- European Network of Gynaecological Oncological Trial Groups (ENGOT)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population
- PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death−Ligand 1 (PD-L1)−Positive Subpopulation
- Overall Survival - ITT Population
- (and 10 more...)
|
1300 |
Female |
18 Years and older (Adult, Senior) |
NCT03038100 |
YO39523 2016-003472-52 |
IMagyn050 |
March 8, 2017 |
April 1, 2020 |
December 1, 2021 |
January 31, 2017 |
April 10, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - St. Joseph'S Hospital & Medical Center
Phoenix, Arizona, United States - Mayo Clinic Arizona
Scottsdale, Arizona, United States - (and 356 more...)
|
36 |
NCT02201992 |
Recruiting |
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) |
- ALK Gene Rearrangement
- ALK Gene Translocation
- ALK Positive
- (and 5 more...)
|
- Other: Clinical Observation
- Drug: Crizotinib
- Other: Laboratory Biomarker Analysis
|
Interventional |
Phase 3 |
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Disease free survival (DFS)
- Toxicity rates, determined using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
378 |
All |
18 Years and older (Adult, Senior) |
NCT02201992 |
E4512 NCI-2014-01507 s16-02072 U10CA180820 U10CA180830 U10CA021115 U24CA196172 |
|
August 18, 2014 |
May 1, 2022 |
|
July 28, 2014 |
December 11, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1286 more...)
|
37 |
NCT02154490 |
Recruiting |
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer |
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
|
- Drug: Docetaxel
- Biological: Durvalumab
- Drug: Erlotinib Hydrochloride
- (and 10 more...)
|
Interventional |
Phase 2 Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Investigator-assessed progression-free survival as defined by Response Evaluation Criteria in Solid Tumors 1.1 (Design #1, Phase II)
- Investigator-assessed progression-free survival in patients with advanced stage refractory squamous cell carcinoma of the lung randomized to receive investigational therapy vs standard therapy (Design #2,Phase III,Option for Biomarker-driven sub-studies)
- Less than 33% improvement in median investigator-assessed progression-free survival as defined as Response Evaluation Criteria in Solid Tumors 1.1 (Design #1, Phase III)
- (and 13 more...)
|
10000 |
All |
18 Years and older (Adult, Senior) |
NCT02154490 |
S1400 NCI-2014-00627 S1400A S1400E S1400I S1400C S1400D S1400B U10CA180888 |
|
June 16, 2014 |
April 1, 2022 |
April 1, 2022 |
June 3, 2014 |
March 21, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 972 more...)
|
38 |
NCT01805076 |
Recruiting |
MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer |
- Estrogen Receptor-negative Breast Cancer
- Progesterone Receptor-negative Breast Cancer
- Stage IA Breast Cancer
- (and 3 more...)
|
- Procedure: Breast surgery
- Procedure: Magnetic resonance imaging
- Procedure: Mammography
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- American College of Radiology Imaging Network
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Local-regional recurrence (LRR)
- Re-operation rate
- Conversion rate to mastectomy secondary to persistent positive margins or poor cosmesis
- (and 6 more...)
|
536 |
Female |
18 Years and older (Adult, Senior) |
NCT01805076 |
A011104 ACRIN 6694 U10CA037447 NCI-2012-02045 |
|
February 2014 |
September 2019 |
|
March 6, 2013 |
April 5, 2018 |
|
- Banner MD Anderson Cancer Center
Gilbert, Arizona, United States - Fowler Family Center for Cancer Care
Jonesboro, Arkansas, United States - Kaiser Permanente-Deer Valley Medical Center
Antioch, California, United States - (and 162 more...)
|
39 |
NCT01368588 |
Recruiting |
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer |
|
- Radiation: radiation therapy
- Radiation: Whole-pelvic radiotherapy (WPRT)
|
Interventional |
Phase 3 |
- Radiation Therapy Oncology Group
- National Cancer Institute (NCI)
- NRG Oncology
- Radiation Therapy Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Cause-specific survival
- Distant metastasis-free survival
- (and 6 more...)
|
2580 |
Male |
18 Years and older (Adult, Senior) |
NCT01368588 |
RTOG-0924 CDR0000701128 NCI-2011-02674 |
|
July 2011 |
July 2027 |
|
June 8, 2011 |
May 19, 2017 |
|
- Providence Cancer Center
Anchorage, Alaska, United States - Arizona Center for Cancer Care - Peoria
Peoria, Arizona, United States - Saint Agnes Cancer Center at Saint Agnes Medical Center
Fresno, California, United States - (and 147 more...)
|
40 |
NCT01349881 |
Recruiting |
S0820, Adenoma and Second Primary Prevention Trial |
|
- Drug: Eflornithine placebo & sulindac placebo
- Drug: eflornithine & sulindac placebo
- Drug: Eflornithine placebo & sulindac
- Drug: Eflornithine plus sulindac
|
Interventional |
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Cancer Prevention Pharmaceuticals, Inc.
- Southwest Oncology Group
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- 3-year event rate after registration among Stage 0-III colon cancer patients. (An event is defined as high-risk adenoma or second primary colorectal cancer.)
- Incidence of colorectal lesions with respect to high-grade dysplasia, adenomas with villous features, adenomas 1 cm or greater, multiple adenomas, polyps >/= 0.3 cm, total advanced colorectal events or total colorectal events at 3 years.
- Toxicity by CTCAEv.4.0 at 3 years
- (and 3 more...)
|
1340 |
All |
18 Years and older (Adult, Senior) |
NCT01349881 |
S0820 U10CA037429 NCI-2012-02067 |
PACES |
March 2013 |
June 2024 |
June 2029 |
May 9, 2011 |
March 21, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 922 more...)
|
41 |
NCT03180294 |
Recruiting |
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer |
- Breast Carcinoma
- Cervical Carcinoma
- Ovarian Carcinoma
- (and 4 more...)
|
- Drug: Bupropion Hydrochloride
- Other: Placebo
|
Interventional |
Phase 2 |
- NRG Oncology
- National Cancer Institute (NCI)
- NRG Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Supportive Care
|
- Change in sexual desire, as measured by the desire subscale of the female sexual function index
- Depressive mood as measured by the patient health questionnaire-4
- Fatigue as measured by Patient Reported Outcomes Measurement Information System fatigue scale
- (and 3 more...)
|
234 |
Female |
18 Years and older (Adult, Senior) |
NCT03180294 |
NRG-CC004 NCI-2017-00344 UG1CA189867 |
|
May 31, 2017 |
October 30, 2019 |
May 31, 2027 |
June 8, 2017 |
April 24, 2018 |
|
- Kaiser Permanente-Anaheim
Anaheim, California, United States - Kaiser Permanente-Deer Valley Medical Center
Antioch, California, United States - Kaiser Permanente-Baldwin Park
Baldwin Park, California, United States - (and 298 more...)
|
42 |
NCT02595944 |
Recruiting |
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) |
- Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- Stage II Non-Small Cell Lung Cancer AJCC v7
- Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
- (and 2 more...)
|
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Disease-free survival
- Incidence of toxicity graded according to Common Terminology Criteria for Adverse Events version 4.0
|
714 |
All |
18 Years and older (Adult, Senior) |
NCT02595944 |
NCI-2015-01916 EA5142 s16-02074 U10CA180820 |
ANVIL |
May 6, 2016 |
July 1, 2024 |
|
November 4, 2015 |
April 25, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 731 more...)
|
43 |
NCT03103321 |
Recruiting |
Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer |
- Stage II Prostate Cancer
- Stage IIA Prostate Cancer
- Stage IIB Prostate Cancer
- (and 5 more...)
|
- Other: Internet-Based Intervention
- Other: Best Practice
- Other: Quality-of-Life Assessment
- (and 3 more...)
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Knowledge assessed by Prostate Cancer Treatment questionnaire
- Decisional quality as measured by Decisional Conflict Scale Decisional Regret
- Clinical time required
- (and 2 more...)
|
172 |
Male |
18 Years and older (Adult, Senior) |
NCT03103321 |
A191402CD NCI-2017-00482 |
|
July 14, 2017 |
January 2020 |
July 2020 |
April 6, 2017 |
April 9, 2018 |
|
- Kaiser Permanente-Cadillac
Los Angeles, California, United States - Kaiser Permanente Oakland-Broadway
Oakland, California, United States - Augusta University Medical Center
Augusta, Georgia, United States - (and 23 more...)
|
44 |
NCT02912559 |
Recruiting |
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair |
- Colon Adenocarcinoma
- DNA Repair Disorder
- Lynch Syndrome
- (and 4 more...)
|
- Drug: Atezolizumab
- Drug: Fluorouracil
- Other: Laboratory Biomarker Analysis
- (and 3 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease free survival (DFS)
- Overall survival
- Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events version 4.0
|
700 |
All |
18 Years and older (Adult, Senior) |
NCT02912559 |
NCI-2016-01417 A021502 U10CA180821 |
|
September 12, 2017 |
July 1, 2020 |
July 1, 2020 |
September 23, 2016 |
April 24, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 702 more...)
|
45 |
NCT02466971 |
Recruiting |
Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer |
- Cervical Adenocarcinoma
- Cervical Adenosquamous Carcinoma
- Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- (and 12 more...)
|
- Drug: Cisplatin
- Radiation: External Beam Radiation Therapy
- Radiation: Intensity-Modulated Radiation Therapy
- (and 4 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS)
- Overall survival (OS)
- Metabolic complete response (mCR) assessed by fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET)/computed tomography (CT)
- (and 4 more...)
|
188 |
Female |
18 Years and older (Adult, Senior) |
NCT02466971 |
NCI-2015-00835 NRG-GY006 U10CA180868 |
|
January 15, 2016 |
September 30, 2018 |
September 30, 2018 |
June 9, 2015 |
April 24, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Women's Cancer Care
Anchorage, Alaska, United States - (and 334 more...)
|
46 |
NCT03337724 |
Recruiting |
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer |
|
- Drug: Ipatasertib
- Drug: Paclitaxel
- Drug: Placebo
|
Interventional |
Phase 2 Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Progression-Free Survival (PFS)
- Objective Response Rate (ORR)
- Duration of Response (DOR)
- (and 7 more...)
|
450 |
All |
18 Years and older (Adult, Senior) |
NCT03337724 |
CO40016 2017-001548-36 |
IPATunity130 |
January 6, 2018 |
March 13, 2021 |
March 13, 2021 |
November 9, 2017 |
March 29, 2018 |
|
- UCSD Moores Cancer Center
La Jolla, California, United States - Kaiser Permanente - Oakland
Oakland, California, United States - Emad Ibrahim, Md, Inc
Redlands, California, United States - (and 163 more...)
|
47 |
NCT02595905 |
Recruiting |
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases |
- Breast Carcinoma Metastatic in the Brain
- Deleterious BRCA1 Gene Mutation
- Deleterious BRCA2 Gene Mutation
- (and 6 more...)
|
- Drug: Cisplatin
- Other: Laboratory Biomarker Analysis
- Other: Placebo
- Drug: Veliparib
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS)
- Overall survival (OS)
- Response rate (measurable disease only)
- Clinical benefit rate
|
333 |
All |
18 Years and older (Adult, Senior) |
NCT02595905 |
NCI-2015-01912 S1416 U10CA180888 |
|
July 7, 2016 |
October 31, 2021 |
|
November 4, 2015 |
April 24, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 766 more...)
|
48 |
NCT02193282 |
Recruiting |
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) |
- ALK Gene Rearrangement
- EGFR Exon 19 Deletion Mutation
- EGFR NP_005219.2:p.L858R
- (and 5 more...)
|
- Other: Clinical Observation
- Drug: Erlotinib Hydrochloride
- Other: Laboratory Biomarker Analysis
- Other: Placebo
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Disease free survival (DFS) rate, defined as the proportion of patients alive and disease free at 2 years from the date of randomization
- Overall survival (OS) rate defined as the proportion of patients alive at 5 years from date of randomization
- (and 3 more...)
|
450 |
All |
18 Years and older (Adult, Senior) |
NCT02193282 |
NCI-2014-01508 s16-02079 CALGB A081105 A081105 U10CA180821 U10CA180830 U10CA031946 |
|
August 18, 2014 |
November 4, 2020 |
|
July 17, 2014 |
April 23, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1302 more...)
|
49 |
NCT03334487 |
Recruiting |
Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer |
- Cancer - Small Cell Lung Cancer
|
- Drug: Dexamethasone
- Drug: Rovalpituzumab tesirine
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with a High Grade (>= Grade 3) Protocol Specified TEAE
- Change in Participant Reported Outcome EORTC QLQC15-PAL
- Progression Free Survival (PFS)
- (and 5 more...)
|
255 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT03334487 |
M16-292 2017-003173-33 |
|
March 15, 2018 |
September 19, 2020 |
September 19, 2020 |
November 7, 2017 |
March 21, 2018 |
|
- Ironwood Cancer & Res Ctr
Chandler, Arizona, United States - VA Central California Health C
Fresno, California, United States - Loma Linda University Medical
Loma Linda, California, United States - (and 56 more...)
|
50 |
NCT01953588 |
Recruiting |
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery |
- Estrogen Receptor-positive Breast Cancer
- HER2-negative Breast Cancer
- Invasive Ductal Breast Carcinoma
- (and 6 more...)
|
- Drug: fulvestrant
- Drug: anastrozole
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of endocrine resistant disease-(First Phase)
- Pathologic complete response rate-(pCR rate)
- Recurrence-free survival (RFS)-(Second Phase)
|
1455 |
Female |
18 Years and older (Adult, Senior) |
NCT01953588 |
A011106 NCI-2013-01340 U10CA031946 |
|
December 2013 |
April 2020 |
|
October 1, 2013 |
April 9, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 790 more...)
|